Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
success tags : Biopharma save search
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
MTNB | $0.18 -4.1% 0.44% 1.4M
|
Health Technology
|
| O: 4.35%
H: 11.21%
C: -0.46%
mat2203 fda treatment biopharma trial agreement
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
Published: 2024-02-16 (Crawled : 23:00) - prnewswire.com
YS | $0.7433 2.47% 2.41% 87K
|
n/a
| Email alert
Add to watchlist
biopharma removal results
Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
Published: 2023-06-24 (Crawled : 12:20) - prnewswire.com
CTIC | $9.09 0.05% 11M
|
Health Technology
| Email alert
Add to watchlist
biopharma
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
Published: 2023-04-05 (Crawled : 16:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M
|
Health Technology
|
| O: 0.75%
H: 1.48%
C: -2.22%
nm-136 fda obesity biopharma meeting
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
Published: 2022-08-30 (Crawled : 13:20) - biospace.com/
CNTB | $1.41 -8.44% -9.22% 51K
|
Professional, Scientific, and T...
|
| O: 0.35%
H: 1.39%
C: -2.08%
cbp-174 biopharma study phase 1
Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program
Published: 2022-07-19 (Crawled : 16:00) - biospace.com/
PPCB | $0.0011 -41.86% 5.6M
|
Manufacturing
|
| O: 0.0%
H: 8.0%
C: -8.0%
biopharma drug research program
BioPharma Services Inc., a Think Research Subsidiary, Achieves Another Successful FDA Inspection Result
Published: 2022-06-16 (Crawled : 15:00) - prnewswire.com
ARMV | $0.005 2214.82% 350
|
| Email alert
Add to watchlist
fda biopharma research services
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
Published: 2022-03-31 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.36 0.91% -0.52% 1.6M
|
Health Technology
|
| O: -0.14%
H: 0.49%
C: -0.62%
biopharma acquisition cardiovascular drug
Biggest Biopharma Successes and Flops of 2021
Published: 2022-01-03 (Crawled : 06:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
IBIO | $1.785 3.78% -0.28% 100K
|
Health Technology
|
| O: 0.18%
H: 10.31%
C: 10.2%
biopharma
Enteris BioPharma Announces Successful Completion of Phase 1 Clinical Trial of Optimized Peptelligence® Oral Leuprolide
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
SWKH | $17.4 -1.64% -1.67% 8.1K
|
Miscellaneous
|
| O: -0.76%
H: 5.82%
C: 3.62%
biopharma phase 1 trial phase 3 phase 2
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children
Published: 2021-05-26 (Crawled : 13:15) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M
|
Health Technology
|
| O: 0.0%
H: 5.04%
C: 0.84%
biopharma children syndros
Freeline Appoints Colin Love, PhD to Board of DirectorsExperienced biopharmaceutical executive with established record of successfully developing, manufacturing and launching impactful therapies
Published: 2021-03-11 (Crawled : 14:01) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 3.71%
H: 0.0%
C: -3.17%
biopharma therapy
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.